Obesity, Cardiovascular Risk and Pharmacotherapy

Author：

ISSN： 0803-7051

Source： Blood Pressure, Vol.11, Iss.5, 2002-11, pp. : 260-262

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy

Current Vascular Pharmacology, Vol. 16, Iss. 2, 2018-01 ,pp. : 130-142

Bentham Science Publishers

Access to resources Recommend Favorite

Gene-Lifestyle and Gene-Pharmacotherapy Interactions in Obesity and Its Cardiovascular Consequences

Current Vascular Pharmacology, Vol. 9, Iss. 4, 2011-07 ,pp. : 401-456

Bentham Science Publishers

Access to resources Recommend Favorite

Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk

Current Vascular Pharmacology, Vol. 14, Iss. 5, 2016-09 ,pp. : 415-425

Bentham Science Publishers

Access to resources Recommend Favorite

Race and Ethnicity, Obesity, Metabolic Health, and Risk of Cardiovascular Disease in Postmenopausal Women

JOURNAL OF THE AMERICAN HEART ASSOCIATION, Vol. 4, Iss. 5, 2015-05 ,pp. : n/a-n/a

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Current Role of Liraglutide in the Pharmacotherapy of Obesity

Current Vascular Pharmacology, Vol. 14, Iss. 2, 2016-03 ,pp. : 201-207

Bentham Science Publishers

Access to resources Recommend Favorite